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eases and stroke were the most consistent endpoints
across the studies but the number and types of endpoints
that were included differed significantly among the stud-
ies. Only two studies included within-clinical trial treat-
ment effectiveness data, whereas the remaining studies
modeled treatment effects from previously published tri-
als. The projected cardiac event rates and life expectancy
were most often derived and estimated from the Framing-
ham study. Treatment costs were obtained from several
different sources outside clinical trials, and only one
study considered costs solely from the trial. CONCLU-
SION: Despite the increasing emphasis on hypertension
as one of the most costly long-term diseases, and the need
to reduce costs associated with it, there are relatively few
recently published studies on the cost-effectiveness of an-
tihypertensive therapies. Methodologically, these pub-
lished studies are very different and they do not seem to
agree on a common way to provide a cost-effectiveness
measure for hypertension treatment, making interpreta-
tions and comparability of results across different studies
more difficult.
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OBJECTIVE: To determine compliance and persistence
with cholesterol-lowering therapy with HMG-CoA re-
ductase inhibitors (statins) in patients following a myo-
cardial infarction (MI) or other atherosclerotic event.
METHODS: Patients were identified from a Midwestern
managed care organization (MCO) database who had an
MI or other atherosclerotic event in 1997 or 1998 and
were continuously enrolled in the MCO for the year fol-
lowing the event. Patient records were collected following
HEDIS reporting guidelines. Pharmacy claims data re-
view identified 216 patients who had at least one pre-
scription filled for a statin. Compliance and persistence
were assessed using length of therapy, single-interval
medication availability, multiple-refill-interval medica-
tion availability, single-interval medication gaps, and
multiple-refill-interval medication gaps. RESULTS: The
population was predominantly male (76%) and the mean
age was 61 years (SD 10.2 years, range 34 to 77). The
cardiovascular events were as follows: 52% MI, 45%
coronary atherosclerosis, and 4% other atherosclerotic
event. The proportion of patients persistent with statin
therapy at 3, 6, 9, and 12 months were 88, 86, 80, and
69 percent respectively. Patients achieved 90% compli-
ance with each refill (SD 25%, median 94) and cumula-
tive compliance for all refills was 83% (SD 24%, median
92). The average single-interval treatment gap was 11
days (SD 28.5 days, median 2 days) while the average cu-
mulative total treatment gap over the study period was
44 days (SD 70 days, median 13 days). CONCLUSIONS:
Compliance with HMG-CoA reductase inhibitors as
measured by single-interval and multiple-refill-interval
was generally high, but not ideal (100%) following an
MI or other atherosclerotic event. These pharmacy claims
data may be further analyzed using multivariate regres-
sion to determine the impacts of age, sex, diagnosis, num-
ber of concomitant medications, medication days supply,
type of statin prescribed, and patient copay on compli-
ance and persistence with therapy.
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OBJECTIVE: There are now a host of HMG-CoA reduc-
tase inhibitors (statins) for treating persons with elevated
cholesterol levels. The objective of this is to determine the
relative cost of treatment among statins. METHODS:
The ACCESS study was a 54-week open label trial of
atorvastatin as compared to fluvastatin, lovastatin, sim-
vastatin and pravastatin. After a screening phase and a
lead-in phase, patients were treated to NCEP target LDL-C
levels with statins, starting at the lowest dose level. At
six-week intervals (weeks 6, 12, 18) patients who had not
yet reached their LDL-C target were titrated up to the
next dose level, to a maximum of 40–80 mg, depending
on the statin. Costs of services used were recorded, in-
cluding: study medications, physician visits, laboratory
and diagnostic tests associated with cholesterol treatment
and other medical services associated with adverse
events. RESULTS: A total of 3916 patients were enrolled
in ACCESS, with 3262 patients completing the study. Pa-
tients treated with atorvastatin had the highest rate of
NCEP goal achievement (76.3% v. 34.2%–57.9%; P 
0.01 for each comparison). As a result of NCEP goal
achievement, atorvastatin-treated patients required the
fewest physician visits through weeks 6–18 (2.81 v. 2.95–
3.45; p  0.01 for each comparison) and the lowest di-
rect study cost per patient achieving NCEP goal ($915 v.
$1393–$2421; p  0.01 for each comparison)—the ulti-
mate measure of cost-effectiveness. CONCLUSIONS:
The ACCESS trial demonstrates that treatment with ator-
vastatin yielded the highest proportion of patients reach-
ing NCEP LDL-C goals at the lowest cost per patient.
